Strategic Partnerships AIP is actively engaging in collaborations with GlobeStar Therapeutics to design clinical studies and pursue MS-focused therapies, indicating a receptive channel for co-development and joint ventures in radiopharmaceuticals and personalized medicine.

Clinical Stage Focus As a clinical-stage radiopharmaceutical company, AIP presents opportunities to supply specialized imaging and therapeutic radiopharmaceuticals, CRO partnerships, and consulting services to accelerate trial design and regulatory submissions.

MS Treatment Potential Recent partnerships around multiple sclerosis (Project Amethyst) highlight a market where neurodegeneration-focused radiopharmaceuticals could be sought after by larger biopharma and speciality clinics seeking imaging diagnostics and trial support.

Revenue Signal Current revenue range indicates early commercial activity with room to scale; sales teams can target mid-market biopharma, specialty biotech firms, and CROs seeking niche nuclear medicine capabilities.

Tech and Outreach Readiness Digital presence and tech stack (Wix/WordPress, Google Cloud, SEO tools) plus a lean team suggest readiness for targeted marketing, partner portals, and streamlined contract workflows to support scalable BD efforts.